This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Amphastar Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 11:15 AM
Amphastar Pharmaceuticals Insider Sold Shares Worth $842,883, According to a Recent SEC Filing MT
JPMorgan Initiates Amphastar Pharmaceuticals With Overweight Rating, Price Target is $60 MT
Sector Update: Health Care Stocks Advance Premarket Thursday MT
Amphastar Pharmaceuticals Q4 Adjusted Earnings, Revenue Rise MT
Transcript : Amphastar Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Amphastar Pharmaceuticals, Inc. Reports Impairment of Long-Lived Assets for the Fourth Quarter Ended December 31, 2023 CI
Amphastar Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Posts Q4 EPS $0.88, vs. Street Est of $0.91 MT
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Reports Q4 Revenue $178.1M, vs. Street Est of $173.3M MT
High-dose opioid reversal spray no better than lower dose in field, US study finds RE
Amphastar Pharmaceuticals Insider Sold Shares Worth $7,171,768, According to a Recent SEC Filing MT
Amphastar Pharmaceuticals Insider Sold Shares Worth $12,798,708, According to a Recent SEC Filing MT
Transcript : Amphastar Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 09:00 AM
MannKind Restructures Supply Agreement with Amphastar Pharmaceuticals MT
Amphastar Pharmaceuticals Insider Sold Shares Worth $223,446, According to a Recent SEC Filing MT
BofA Securities Initiates Amphastar Pharmaceuticals at Neutral Rating With $63 Price Target MT
Amphastar Pharmaceuticals Insider Sold Shares Worth $262,500, According to a Recent SEC Filing MT
Amphastar Pharmaceuticals Q3 Adjusted Non-GAAP Earnings, Revenue Rise MT
Transcript : Amphastar Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 08, 2023
Tranche Update on Amphastar Pharmaceuticals, Inc.'s Equity Buyback Plan announced on November 8, 2016. CI
Amphastar Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Posts Q3 EPS $1.15, vs. Street Est of $0.69 MT
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Reports Q3 Revenue $180.6M, vs. Street Est of $173.8M MT
Amphastar Pharmaceuticals Prices $300 Million Senior Notes Offering MT
Chart Amphastar Pharmaceuticals, Inc.
More charts
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
40.83 USD
Average target price
62.6 USD
Spread / Average Target
+53.32%
Consensus
  1. Stock Market
  2. Equities
  3. AMPH Stock
  4. News Amphastar Pharmaceuticals, Inc.
  5. Amphastar Pharmaceuticals Secures FDA Approval for Regadenoson